Alnylam Pharmaceuticals
New reports from Alnylam Pharmaceuticals detailed
Published in Medical Patent Law Weekly, February 7th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Alnylam Pharmaceuticals.
Report 1: Alnylam Pharmaceuticals, Inc., (ALNY) will advance a systemically delivered RNAi therapeutic for the treatment of hypercholesterolemia as its next clinical development program.
This program, in collaboration with University of Texas (UT) Southwestern Medical Center at Dallas, is focused on evaluating new approaches for reducing LDL cholesterol levels using RNAi therapeutics directed to the disease target called proprotein convertase...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
More Articles from Medical Patent Law Weekly
- Alzheimer Disease
IBL, Intellect enter into humanized monoclonal antibodies development agreement - Antibacterial Agents
Patents of leading antibiotics expire, will constrain the antibacterial market - Biomedical Engineering
New biomedical engineering study findings have been reported from Ruhr University, Institute for Biomedical Engineering - Business & Finance
ArthroCare expects fourth quarter 2006 revenues of approximately $69.7 million - Business Update
Alnylam reports key product and business goals for 2007 - Business Update
CytRx Corporation establishes RNAi subsidiary, RXi Pharmaceuticals - More from this issue of Medical Patent Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
